74,100
-0.94%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About OliX Pharmaceuticals
Its shares trade on KOSDAQ under the ticker 226950.KQ. It has been listed since 18 July 2018. In the fiscal year to 31 December 2025, it reported revenue of ₩14.67bn and a net loss of ₩15.74bn. At that date it held total assets of ₩195.37bn and shareholders' equity of ₩149.38bn.
OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. The company is headquartered in Suwon, Gyeonggi-Do. The company went IPO on 2018-07-18. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The firm operates its business within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jul 2018
- Employees
- 72
- Website
- olixpharma.com ↗
Leadership
Pay as last reported
- Mr. Dong Gi LeeChief Executive Officer, Director₩831.0m
- Ms. Sin Yeong ParkSenior Vice President, Director
- Mr. Chung Gil KangVice President, Director
- Ms. Yeong Hye BaekAssistant Managing Director
- Mr. Wu Tae JeonInternal Auditor
- Mr. Chang Su YoonOther Non-Executive Director
- Mr. Tae Gyeong KimNon-Executive Independent Director
- Mr. Yang Gyun KimNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- OliX Pharmaceuticals employs 72 full-time employees focused on biotechnology research and development.
- OliX Pharmaceuticals' product portfolio includes OLX101, OLX102, OLX103, and OLX104 for skin treatments.
- The company's products address multiple medical conditions including hypertrophic scars, keloids, and diabetic ulcer.
Weaknesses
- OliX Pharmaceuticals has limited domestic market presence in South Korea.
- The company's product range lacks coverage for cardiovascular diseases and cancer treatments.
- OliX Pharmaceuticals operates with a small employee count of 72 staff members.
Opportunities
- OliX Pharmaceuticals can expand its product line to include treatments for cardiovascular diseases.
- The company can target overseas markets for its skin brightening and anti-wrinkle products.
- OliX Pharmaceuticals may leverage its existing product portfolio for new medical applications.
Threats
- OliX Pharmaceuticals faces competition from established biotechnology firms in South Korea.
- The company's reliance on a limited product portfolio poses a risk to market stability.
- OliX Pharmaceuticals must navigate regulatory challenges in overseas markets for drug approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.